ABSTRACT. Objective. The introduction of heptavalent conjugate pneumococcal vaccine (PCV7) has raised concerns for replacement with nonvaccine serotypes in both invasive disease and asymptomatic carriage. Analysis of colonizing serotypes among healthy children in the community provides critical data on such changes.
B
efore the release of a conjugate vaccine for US children, Streptococcus pneumoniae caused invasive disease in 1 in 500 to 600 children who were younger than 2 years. 1 In addition, rising antibiotic resistance among pneumococcal strains was a major concern among public health officials. 2, 3 By 1999, 38% of laboratory isolates in children who were younger than 2 years were nonsusceptible to penicillin, 4 with higher rates reported in local areas. [5] [6] [7] In February 2000, heptavalent pneumococcal conjugate vaccine (PCV7) was released to provide immunity to the 7 serotypes responsible for 85% of pediatric invasive pneumococcal disease 8 and 78% of penicillin-nonsusceptible S pneumoniae (PNSP) isolates in children. 9 Prelicensure trials showed a 90% reduction in invasive disease 10 and a 23% reduction in all-cause pneumonia in the first 2 years of life. 11 Postlicensure studies have also shown declines in invasive pneumococcal disease from 188 per 100 000 to 59 cases per 100 000 in US children who are younger than 2 years. 4, 12 Despite the success of PCV7 in reducing invasive disease, critical questions remain about the changing pneumococcal reservoir. Some trials of immunization with PCV7 have shown a 50% to 65% decrease in carriage of vaccine serotypes [13] [14] [15] and have raised concerns about replacement of vaccine serotypes with nonvaccine serotypes that may ultimately result in invasive disease. 16, 17 Although, currently, the majority of invasive disease is caused by vaccine-included serotypes, the relationship between carriage of and invasive disease is complex and varies by serotype. 18, 19 Shifts in colonizing serotypes after PCV7 may serve as early indicators of changes in invasive disease.
We assessed secular trends in community-level S pneumoniae carriage and resistance after the licensure of PCV7. Community-level analyses assess the full impact of both direct and indirect (herd immunity) effects of vaccines. In 2001, we conducted surveillance for pneumococcal carriage among generally healthy children in 16 distinct Massachusetts communities. 20 At that time, just after introduction of PCV7, we found that 26% of children carried S pneumoniae overall and that PCV7 serotypes accounted for 36% of isolates. 20 Resistance to penicillin (and other antimicrobials) was concentrated among PCV7 serotypes and potentially cross-reactive serotypes, with penicillin nonsusceptibility of 45% and 51%, respectively. By November 2003, all children through 3.5 years of age were born into the era of routine PCV7 immunization in infancy. In this context, we resampled the same 16 communities in the winter and spring of 2003-2004 to determine (1) changes in carriage of PCV serotypes, PCV7 cross-reactive serotypes, and non-PCV7 S pneumoniae serotypes; (2) changes in overall antimicrobial resistance; and (3) serotype-specific changes in antimicrobial resistance.
METHODS

Data Collection
Nasopharyngeal specimens were collected from young children in pediatric and family practice physician offices in 16 Massachusetts communities between November 17, 2003, and April 16, 2004 . We had performed surveillance in the same 16 communities from March 13 to May 11, 2001 , as part of the baseline microbiologic data collection for a randomized trial of community-level intervention to promote judicious antibiotic prescribing for children. 20 These 16 communities were selected on the basis of physical geographic separation, evidence that few children crossed community boundaries to seek pediatric care, and diversity of size and demographic characteristics using available US Census data. In 2001, 31 private practice offices participated, and in 2004, 23 offices participated, all of which had participated in 2001.
In 2001, children were eligible for inclusion if they were younger than 7 years, resided in a study community, and presented for either a routine well-child or "sick visit" at a participating practice. 20 Parental consent and nasopharyngeal swabs were obtained by either trained study personnel or trained office practice nurses. PCV7 vaccination history was recorded from the medical record. In 2004, to increase sample size, we modified criteria to include children who received care in the study practices and lived beyond the zip code boundaries of the community. Recruitment in 2004 was independent of participation in 2001. All study procedures were approved by the Harvard Pilgrim Health Care institutional review board.
Microbiologic Processing
Nasopharyngeal samples were processed for S pneumoniae growth, antibiotic susceptibility, and serotype as previously described. 20 Standard National Committee for Clinical Laboratory Standards susceptibility breakpoints were used to classify organisms as susceptible, intermediate, and resistant. 21 Two definitions of multidrug resistance (MDR) were used: resistance to the ␤-lactam class plus 1 other antibiotic class (MDR1) and resistance to at least 3 antibiotic classes (MDR2). Penicillins, cephalosporins, and carbapenems were considered a single class. Comparisons of third-generation cephalosporin resistance were performed using 2004 breakpoint criteria. 21, 22 We had previously reported carriage data from 2001 using the breakpoint criteria at that time. These 2001 data were reanalyzed with 2004 criteria for this analysis.
Serotypes included in the PCV7 were considered vaccine serotypes, and serotypes from serogroups that were not in PCV7 were considered nonvaccine serotypes. Serotypes in the same serogroup as vaccine serotypes (eg, 6A and 6B both are serogroup 6 strains) but not specifically included in the vaccine were classified as potentially cross-reactive serotypes. The extent to which the vaccine provides protection in vivo varies by serotype, but there is likely to be clinically important cross-protection against some of these strains. For quality control, we reserotyped a 36% random sample (82 of 226) of pneumococcal isolates from 2004 in a blinded manner and calculated percentage concordance.
Data Analysis
Microbiologic data were analyzed using SAS software version 8.2 (SAS Institute, Cary, NC). Proportions of children who carried S pneumoniae and proportions of isolates that were nonsusceptible to antibiotics were calculated and compared between the 2004 and previously published 2001 sample 20 using Fisher exact tests. Carriage proportions were calculated by sampling period and by age group (Ͻ6 months, 6 -Ͻ12 months, 12-Ͻ24 months, 24 -Ͻ36 months, and Ն36 months). Resistance patterns were analyzed for the 2004 sample, by vaccine group (PCV7, PCV7 cross-reactive, and non-PCV7 serotypes) and by individual serotype and compared with the 2001 sample.
RESULTS
We collected 996 nasopharyngeal samples from children in 23 practices from November 17, 2003, through April 16, 2004 (Table 1) , 2 of which were lost in transit. Of the 994 remaining samples, 73% (726) came from children who lived within the specified 16 Massachusetts communities described in Table 2 ; the remainder were patients of these practices who lived outside the designated community zip codes. Because pneumococcal carriage and descriptive characteristics of these children were similar to those who lived within the designated zip codes, data were combined for analysis. Fifteen percent (153) of participants were siblings of other participants, compared with 12% (87) Fig 1) . The proportion of PCV7 cross-reactive isolates remained stable. In all age groups, the proportion of PCV7 strains carried decreased, whereas the proportion of non-PCV7 serotypes either remained the same (Ͻ6-month-olds) or increased (all other age groups). There was no difference in the proportion of serotypes included in the 23-valent adult pneumococcal polysaccharide vaccine between 2001 (57%; 82 (Fig 2) . Serotype 19F showed minimal decline and thus increased proportionally among PCV7 serotypes from 31% ( Overall carriage of a PNSP isolate was similar in 2001 (7%; 49 of 695) and 2004 (9%; 86 of 988). However, penicillin nonsusceptibility declined among PCV7 isolates and increased among non-PCV7 isolates (Fig 1) . The former reflected a decrease in highlevel penicillin-resistant isolates, whereas the latter 
TABLE 3.
Overall Pneumococcal Serotypes and Antibiotic Resistance by Surveillance Period* Serotypes Year PCN-I, % (n) (6) 33% (17) 45% (23) 35% (18) 12% (6) 41% (21) 27% (14) 43% (22) 31% (16) 2004 19% (6) 38% (12) 56% (18) 34% (11) 13% (4) 47% (15) 6% (2) 44% (14) 38% (12 (22) 19% (8) 0% (0) 51% (22) 16% (7) 40% (17) 9% (4) 2004 43% (30) 10% (7) 54% (37) 32% (22) 4% (3) 26% (18) 4% (3) 35% (24) 
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reflected an increase in intermediate resistance to penicillin (Table 3) . Penicillin nonsusceptibility varied among commonly carried serotypes. In 2004, the proportion of PNSP was 64% in 6A, 0% in 11A, 38% in 15, 65% in 19A, 65% in 19F, 36% in 23A, and 74% in 29 (see Fig  2) .
Changes in susceptibility to additional antibiotics is shown in Table 3 . Notably, among non-PCV7 serotypes, nonsusceptibility significantly increased for penicillin, clindamycin, and MDR (Table 3 ). The proportion of isolates that were resistant to 3 or more antibiotic classes increased from 9% (4 of 43) to 20% (14 of 69) among PCV7 cross-reactive serotypes and from 2% (1 of 49) to 10% (13 of 125) among non-PCV7 serotypes.
DISCUSSION
The licensure of PCV7 was accompanied by projections of decreased S pneumoniae carriage, invasive disease, and antibiotic resistance. 13, 15, 17 When evaluating young healthy children in the same 16 Massachusetts communities in 2001 and 2004, we found significantly increased carriage of nonvaccine strains and increased antibiotic resistance among nonvaccine serotypes.
Despite the significant decline in PCV7 serotypes, overall pneumococcal carriage did not change between 2001 and 2004 because of significant increases in the carriage of non-PCV7 serotypes. This serotype replacement was seen in all pediatric age groups studied and resulted in similar proportions of pneumococcal carriage in age groups between 6 and 36 months for both sampling periods. Among children who were Ն36 months of age, overall carriage declined between 2001 and 2004. This is not surprising given differential vaccination of children of this age in 2004 compared with 2001 (unlikely to be vaccinated unless at high risk). By contrast, we have no clear explanation for the observed increased rate of carriage among young infants (Ͻ6 months).
These changes suggest a rapid replacement of vaccine serotypes by nonvaccine serotypes, either by the unmasking of previous minority strains 24 or by replacement of previous PCV7 carriage by serotypes unaffected by vaccine immunity. Another possibility is serotype switch, 25 whereby pneumococcal strains express a new capsular serotype, possibly to evade host immunity. This phenomenon has been described between 15B and 15C, 26 19F and 23F, 27 9V and 11A, 28 and others. 25 Although serotype replacement has been a concern after the release of the conjugate pneumococcal vaccine, experts hoped that antibiotic resistance would decrease because resistance had been highly concentrated in PCV7 and PCV7 cross-reactive serotypes. 1, 20, 29 As hoped, our serial community-based sampling showed that high-level penicillin resistance declined 38% and nonsusceptibility to third-generation cephalosporins decreased 88% across all isolates. However, this reduction in high-level penicillin resistance, produced by the reduction in carriage of certain PCV7 and PCV7 cross-reactive serotypes, was offset by increased carriage of nonvaccine serotypes, in which intermediate penicillin resistance has risen significantly. Antibiotic resistance among non-PCV7 pneumococcal serotypes (which had been negligible in 2001) increased to 25%, and resistance to 3 or more antibiotic classes increased to 10%.
In addition to increasing intermediate penicillin resistance, non-PCV7 strains showed an increase in clindamycin nonsusceptibility that was highly associated with macrolide resistance. Until now, most S pneumoniae isolates that are resistant to macrolides in the United States have displayed the M phenotype, related to a macrolide-specific efflux mechanism. 30 The mechanism of resistance associated with dual macrolide and clindamycin resistance is related to the MLS phenotype, which is a result of target modification at the 50S ribosomal subunit. 30 As the prevalence of non-PCV7 carriage increases, antibiotic exposure may be providing a selective pressure toward the emergence of additional resistance in these serotypes.
These data must be interpreted with the following caveats. First, we assume that carriage among children who seek care from primary care providers reflects carriage in their community. Although this assumption depends on the distribution of patients in a given practice, we believe it to be better than sampling schemes in child care settings that likely overrepresent shared colonizing strains. Second, the surveillance period occurred later in the season in 2001 compared with 2004 and may have affected carriage prevalence slightly, although we expect the proportion of serotypes among carriers to be unaffected. Third, because we sampled only twice, it is possible that we have observed natural fluctuations in the pneumococcal carriage state, rather than a trend related to the introduction of pneumococcal conjugate vaccine. We believe this unlikely given the magnitude and consistent direction of the shifts.
These data provide insight into the impact of PCV7 on pneumococcal carriage in young children. All communities included both immunized and unimmunized children, but, by 2004, all children who were younger than 42 months were born after routine PCV7 immunization began. As reflected in our study subjects, Massachusetts has one of the highest documented immunization rates in the United States. 31 In this sample, we find evidence for in-
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POST-PCV7 SHIFTS IN PNEUMOCOCCAL CARRIAGE creased carriage of non-PCV7 serotypes among vaccinated children who were older than 12 months. It remains to be seen whether invasive infections caused by non-PCV serotypes will become more common. Recent data 32 suggest that nonvaccine serotypes, including novel ones, 33, 34 may become important pathogens and that increased antibiotic resistance among these strains 33, 34 may have adverse consequences for children over time. Continued evaluation of the pneumococcal reservoir may presage changes in strains that are responsible for localized and invasive disease as a result of the widespread use of PCV7. Such information may inform clinicians' expectations of antibiotic resistance in pneumococcal infections as well as development of the next generation of conjugate pneumococcal vaccines.
